We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Highly Sensitive Liquid Biopsy Technique Brings Personalized Cancer Monitoring a Step Closer

By LabMedica International staff writers
Posted on 29 Jun 2020
A modified liquid biopsy method enables detection of circulating tumor DNA (ctDNA) with much greater sensitivity than previously used techniques and demonstrates the potential to revolutionize all aspects of cancer care, from early detection to personalized treatment and monitoring.

While ctDNA can be used to monitor cancer dynamics noninvasively, detecting it can be challenging in patients with low-volume or residual disease, where the plasma contains very few tumor-derived DNA fragments. More...
Investigators at the University of Cambridge (United Kingdom) and their collaborators sought to develop a method for ctDNA detection with greatly increased sensitivity. To this end, they showed that sensitivity for ctDNA detection in plasma could be improved by using the INtegration of VAriant Reads (INVAR) pipeline. This technique combined custom error-suppression methods and signal-enrichment approaches based on biological features of ctDNA to analyze hundreds to thousands of mutations.

Current liquid biopsies search for around 10-20 mutations and up to around 100 in blood samples. Thus, they are able to detect ctDNA to levels on the range of one mutant molecule amongst 30,000 fragments of DNA. In contrast, the INVAR technique searched for hundreds and sometimes thousands of mutations in each blood sample, routinely achieving a sensitivity of one mutant molecule per 100,000, and under optimal conditions reached a level of ctDNA measured in parts per million.

The investigators applied INVAR to custom hybrid-capture sequencing data from 176 plasma samples from 105 patients with melanoma, lung, renal, glioma, and breast cancer across both early and advanced disease. By integrating signal across a median of more than 105 informative reads, ctDNA was routinely quantified to one mutant molecule per 100,000, and in some cases with high tumor mutation burden and/or plasma input material, to parts per million. This resulted in median area under the curve (AUC) values of 0.98 in advanced cancers and 0.80 in early-stage and challenging settings for ctDNA detection.

Senior author Dr. Nitzan Rosenfeld, senior group leader in cancer research at the University of Cambridge, said, “Personalized tests that can detect if cancer is still present, or find it early if it is returning, are now being tested in clinical trials. Whilst this may be several years away from clinical use, our research shows what is possible when we push such approaches to an extreme. It demonstrates that the levels of sensitivity we have come to accept in recent years in relation to testing for ctDNA can be dramatically improved. At present this is still experimental, but technology is advancing rapidly, and in the near future tests with such sensitivity could make a real difference to patients.”

The INVAR approach was described in the June 17, 2020 online edition of the journal Science Translational Medicine.

Related Links:
University of Cambridge


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.